Page 1 | Search Results | Blood | American Society of Hematology

1-11 of 11

Sort by

Sort Order Select

Journal Articles

ADAR1-regulated cytoplasmic dsRNA-sensing pathway is a novel mechanism of lenalidomide resistance in multiple myeloma

Mun Yee Koh, Tae-Hoon Chung, Nicole Xin Ning Tang, Sabrina Hui Min Toh, Jianbiao Zhou, Tze King Tan, Leilei Chen, Wee Joo Chng, Phaik Ju Teoh

Blood blood.2024024429.

https://doi.org/10.1182/blood.2024024429

Published: 2024

Includes: Supplemental data

Journal Articles

Functional Genomics Studies Decipher the Genetic Perturbations and Unravel Mechanisms of Response/Resistance upon Mutant-Specific KRAS Inhibition in Multiple Myeloma

Torsten Steinbrunn, Ryosuke Shirasaki, Olga Dashevsky, Huihui Tang, Shizuka Yamano, Phaik Ju Teoh, Lisa Leypoldt, Brian Glassner, Ricardo De Matos Simoes, James Christensen, Constantine S Mitsiades

Blood (2024) 144 (Supplement 1): 3286.

https://doi.org/10.1182/blood-2024-211598

Published: 2024

Journal Articles

Targeting Mutant KRAS with Novel Mutant-Specific Pharmacological Inhibitors: Activity Against Myeloma and Other Lymphoid Malignant Cells and Molecular Mechanisms of Resistance

Torsten Steinbrunn, Ryosuke Shirasaki, Olga Dashevsky, Huihui Tang, Shizuka Yamano, Rin Mizuno, Takeru Sugihara, Phaik Ju Teoh, Lisa B Leypoldt, Mariko Kaji, Jeffrey Sorrell, Brian J Glassner, Ricardo De Matos Simoes, James Christensen, Constantine S Mitsiades

Blood (2023) 142 (Supplement 1): 4186.

https://doi.org/10.1182/blood-2023-182476

Published: 2023

Journal Articles

Functional Characterization of Genes Residing in Chromosomal Regions with “High-Risk” Lesions in Multiple Myeloma

Phaik Ju Teoh, Ricardo De Matos Simoes, Tae-Hoon Chung, Torsten Steinbrunn, Lisa B Leypoldt, Olga Dashevsky, Francisca Vazquez, Wee-Joo Chng, Constantine S Mitsiades

Blood (2023) 142 (Supplement 1): 3293.

https://doi.org/10.1182/blood-2023-190050

Published: 2023

Journal Articles

Integrated Molecular Landscape of Lesions in Cereblon and Its Pathway in Myeloma Patients: Insights into Mechanisms of Relapse from IMiD-Based Treatments

Lisa B Leypoldt, Torsten Steinbrunn, Phaik Ju Teoh, Ricardo De Matos Simoes, Ryosuke Shirasaki, Constantine S Mitsiades

Blood (2023) 142 (Supplement 1): 3321.

https://doi.org/10.1182/blood-2023-180033

Published: 2023

Journal Articles

Systematic Functional Characterization for Loss of Function Events Cooperating with TP53 Loss in High-Risk 17p13(del) Multiple Myeloma

Phaik Ju Teoh, Ricardo De Matos Simoes, Tae-Hoon Chung, Mick Lee, Olga Dashevsky, Shizuka Yamano, Roger Foo, Wee Joo Chng, Constantine S. Mitsiades

Blood (2022) 140 (Supplement 1): 7110–7111.

https://doi.org/10.1182/blood-2022-159316

Published: 2022

Journal Articles

Elucidating the Role of ADAR1 in Regulating Immunotherapeutic Response in Multiple Myeloma

Mun Yee Koh, Phaik Ju Teoh, Tae-Hoon Chung, Leilei Chen, Wee Joo Chng

Blood (2022) 140 (Supplement 1): 7084–7085.

https://doi.org/10.1182/blood-2022-158848

Published: 2022

Journal Articles

Potential IL6R-ADAR1-STAT3 Interplay Promotes Oncogenicity in 1q21(amp) Multiple Myeloma

Phaik Ju Teoh, PhD, Tae-Hoon Chung, Leilei Chen, PhD, Wee Joo Chng, MB ChB, PhD FRCP(UK), FRCPath, FAMS

Blood (2018) 132 (Supplement 1): 4513.

https://doi.org/10.1182/blood-2018-99-118895

Published: 2018

Journal Articles

Aberrant hyperediting of the myeloma transcriptome by ADAR1 confers oncogenicity and is a marker of poor prognosis

Phaik Ju Teoh, Omer An, Tae-Hoon Chung, Jing Yuan Chooi, Sabrina H. M. Toh, Shuangyi Fan, Wilson Wang, Bryan T. H. Koh, Melissa J. Fullwood, Melissa G. Ooi, Sanjay de Mel, Cinnie Y. Soekojo, Leilei Chen, Siok Bian Ng, Henry Yang, Wee Joo Chng

Blood (2018) 132 (12): 1304–1317.

https://doi.org/10.1182/blood-2018-02-832576

Published: 2018

Includes: Supplemental data

Journal Articles

JMJD3 Is a Potential Tumor Suppressor Gene That Cooperates with TP53 in Chromosome 17p13

Phaik Ju Teoh, PhD, Tae-Hoon Chung, Chirackal Sintosebastian, Rafael Fonseca, MD, Wee Joo Chng, MB ChB, MRCP, PhD

Blood (2017) 130 (Supplement 1): 1761.

https://doi.org/10.1182/blood.V130.Suppl_1.1761.1761

Published: 2017

Journal Articles

PRIMA-1 (p53 Reactivation and Induction of Massive Apoptosis) Mediates Anti-Myeloma Effect through the ER Stress Pathway

Phaik Ju Teoh, Chonglei Bi, Sinto Sebastian, PhD, Rafael Fonseca, MD, Wee Joo Chng, MD PhD

Blood (2014) 124 (21): 2093.

https://doi.org/10.1182/blood.V124.21.2093.2093

Published: 2014

NARROW

ADAR1-regulated cytoplasmic dsRNA-sensing pathway is a novel mechanism of lenalidomide resistance in multiple myeloma

Functional Genomics Studies Decipher the Genetic Perturbations and Unravel Mechanisms of Response/Resistance upon Mutant-Specific KRAS Inhibition in Multiple Myeloma

Targeting Mutant KRAS with Novel Mutant-Specific Pharmacological Inhibitors: Activity Against Myeloma and Other Lymphoid Malignant Cells and Molecular Mechanisms of Resistance

Functional Characterization of Genes Residing in Chromosomal Regions with “High-Risk” Lesions in Multiple Myeloma

Integrated Molecular Landscape of Lesions in Cereblon and Its Pathway in Myeloma Patients: Insights into Mechanisms of Relapse from IMiD-Based Treatments

Systematic Functional Characterization for Loss of Function Events Cooperating with TP53 Loss in High-Risk 17p13(del) Multiple Myeloma

Elucidating the Role of ADAR1 in Regulating Immunotherapeutic Response in Multiple Myeloma

Potential IL6R-ADAR1-STAT3 Interplay Promotes Oncogenicity in 1q21(amp) Multiple Myeloma

Aberrant hyperediting of the myeloma transcriptome by ADAR1 confers oncogenicity and is a marker of poor prognosis

JMJD3 Is a Potential Tumor Suppressor Gene That Cooperates with TP53 in Chromosome 17p13

PRIMA-1 (p53 Reactivation and Induction of Massive Apoptosis) Mediates Anti-Myeloma Effect through the ER Stress Pathway

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only